Abstract:Ischemia/reperfusion (I/R) injury plays a critical role in endothelial dysfunction as a consequence of limited nitric oxide (NO) bioavailability and excess generation of reactive oxygen species (ROS) generated by endothelial nitric oxide synthase (eNOS) during reperfusion. Activated protein kinase C epsilon (PKCɛ) binds to a specific receptor for activated C kinase (RACK‐1), facilitating its translocation from the cytosol to the cell membrane for phosphorylation of targets, such as eNOS, at serine‐1177 to augment activity. Previous in vitro and in vivo animal studies have shown that PKCɛ activation stimulates eNOS activity, increasing NO release; whereas PKCɛ inhibition using a peptide inhibitor that interferes with its interaction with RACK‐1 results in decreased NO release. However, the modulation of PKCɛ‐mediated eNOS activity has yet to be demonstrated in human cells. In this study, we aim to demonstrate enhancement and attenuation of NO release in human umbilical vein endothelial cells (HUVECs) using cell‐permeable, myristic‐acid conjugated PKCɛ activator (Myr‐PKCɛ+), Myr‐HDAPIGYD (MW=1097 g/mol), and inhibitor (Myr‐PKCɛ−), Myr‐EAVSLKPT (MW=1054 g/mol), peptides respectively. Single‐donor HUVECs at passages 3–4 were grown to confluence in 6‐well (35 mm) plates. NO release was measured in real time using a calibrated NO electrode following the administration of 10 μM Myr‐PKCɛ+ or 10 μM Myr‐PKCɛ− treatments in the absence or presence of 10 μM acetylcholine (Ach) stimulation of NO release. Basal NO release (375±175 pM) was determined by measuring the difference between wells with and without cells (n=4). Myr‐PKCɛ+ increased NO levels by 36±13 pM (p<0.01, n=5) and Myr‐PKCɛ− decreased NO levels by 41±55 pM, p<0.01, n=5) significantly compared to baseline in the absence of Ach stimulation. In the presence of 10 μM Ach only, NO release significantly increased by 61±15 pM above baseline (p<0.01, n=5). In Ach‐stimulated cells, there was an additional significant increase in NO release by 70±23 pM (p<0.01, n=5) when treated with Myr‐PKCɛ+ compared to baseline, although there was no significance compared to the initial Ach‐stimulated NO release. Following initial 10 μM Ach administration, Myr‐PKCɛ− significantly reduced NO release by 48±16 pM, (p<0.01, n=5) compared to baseline. These results suggest Myr‐PKCɛ+ presumably increases NO release via activation of eNOS, whereas Myr‐PKCɛ− attenuates eNOS activity by inhibiting its phosphorylation in HUVECs; thus, eNOS modulation by these peptides demonstrate comparable effects across species. Elucidating the role of eNOS modulation is important for developing therapeutic interventions in the context of human organ I/R injury, in which uncoupled eNOS produces ROS instead of NO. Future studies will evaluate the effects of Myr‐PKCɛ+ and Myr‐PKCɛ− on NO release in HUVECs during reperfusion following prolonged ischemia compared to non‐ischemic controls.Support or Funding InformationThis study was supported by the Center for Chronic Disorders of Aging, the Division of Research and the Department of Biomedical Sciences at Philadelphia College of Osteopathic Medicine.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Pyridoxine inhibits endothelial NOS uncoupling induced by oxidized low-density lipoprotein via the PKCα signalling pathway in human umbilical vein endothelial cells.

PKC/NADPH Oxidase Are Involved in the Protective Effect of Pioglitazone in High Homocysteine-Induced Paracrine Dyfunction in Endothelial Progenitor Cells.

Nadph Oxidase Activation Played A Critical Role in the Oxidative Stress Process in Stable Coronary Artery Disease

Inhibition of Superoxide Anion-Mediated Impairment of Endothelium by Treatment with Luteolin and Apigenin in Rat Mesenteric Artery.

XJP-1 Protects Endothelial Cells from Oxidized Low-Density Lipoprotein-Induced Apoptosis by Inhibiting NADPH Oxidase Subunit Expression and Modulating the PI3K/Akt/eNOS Pathway

Pyridoxine Increases Nitric Oxide Biosynthesis In Human Platelets

Phenylephrine-Induced Cardiomyocyte Injury Is Triggered By Superoxide Generation Through Uncoupled Endothelial Nitric-Oxide Synthase And Ameliorated By 3-[2-[4-(3-Chloro-2-Methylphenyl)-1-Piperazinyl]Ethyl]-5,6-Dimethoxyinda Zole (Dy-9836), A Novel Calmodulin Antagonist

The Protein S-nitrosylation of Splicing and Translational Machinery in Vascular Endothelial Cells is Susceptible to Oxidative Stress Induced by Oxidized Low-Density Lipoprotein.

The Oxidized Phospholipid POVPC Impairs Endothelial Function and Vasodilation Via Uncoupling Endothelial Nitric Oxide Synthase.

Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ.

Protective Effect of Uric Acid on ox-LDL-Induced HUVECs Injury via Keap1-Nrf2-ARE Pathway

Ginsenoside compound K protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury via inhibition of nuclear factor-κB, p38, and JNK MAPK pathways

Inhibition of protein kinase C β(2) prevents tumor necrosis factor-α-induced apoptosis and oxidative stress in endothelial cells: the role of NADPH oxidase subunits

Inhibition of Protein Kinase C β<sub>2</sub> Prevents Tumor Necrosis Factor-α-Induced Apoptosis and Oxidative Stress in Endothelial Cells: The Role of NADPH Oxidase Subunits

Pioglitazone Restores the Homocysteine‑impaired Function of Endothelial Progenitor Cells Via the Inhibition of the Protein Kinase C/NADPH Oxidase Pathway.

Endothelial Nitric Oxide Synthase–Derived Nitric Oxide Prevents Dihydrofolate Reductase Degradation Via Promoting S-Nitrosylation

Propofol induces endothelial nitric oxide synthase phosphorylation and activation in human umbilical vein endothelial cells by inhibiting protein kinase Cd expression

Puerarin protects endothelial cells from oxidized low density lipoprotein induced injuries via the suppression of LOX-1 and induction of eNOS

Thioredoxin Attenuates Oxidized Low-Density Lipoprotein Induced Oxidative Stress in Human Umbilical Vein Endothelial Cells by Reducing NADPH Oxidase Activity

Modulation of Nitric Oxide Release in Human Umbilical Vein Endothelial Cells by Myristolated‐PKC Epsilon Activator/Inhibitor Peptides

Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase